🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 20 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 03/01/2000 | 17,75 | 18,78 | 16,81 | 18,78 | +7,32% | 11,09% | 1.010.000 |
| 31/12/1999 | 17,00 | 18,00 | 17,00 | 17,50 | +1,82% | 5,88% | 247.400 |
| 30/12/1999 | 17,22 | 17,25 | 16,81 | 17,19 | -0,36% | 2,54% | 616.000 |
| 29/12/1999 | 17,53 | 18,63 | 17,06 | 17,25 | -1,69% | 8,91% | 314.800 |
| 28/12/1999 | 17,08 | 17,63 | 17,06 | 17,55 | +2,46% | 3,29% | 571.000 |
| 27/12/1999 | 16,63 | 17,94 | 16,38 | 17,13 | +3,79% | 9,40% | 683.600 |
| 23/12/1999 | 14,25 | 17,25 | 14,25 | 16,50 | +18,39% | 21,05% | 1.024.200 |
| 22/12/1999 | 13,38 | 14,06 | 13,38 | 13,94 | +3,00% | 5,14% | 242.000 |
| 21/12/1999 | 13,91 | 14,06 | 13,44 | 13,53 | -2,48% | 4,49% | 459.000 |
| 20/12/1999 | 13,56 | 14,19 | 13,28 | 13,88 | +3,02% | 6,68% | 577.200 |
| 17/12/1999 | 13,31 | 13,50 | 13,25 | 13,47 | +0,12% | 1,88% | 200.400 |
| 16/12/1999 | 13,53 | 14,00 | 13,19 | 13,45 | -0,35% | 6,00% | 472.600 |
| 15/12/1999 | 13,19 | 13,63 | 13,19 | 13,50 | +1,41% | 3,32% | 265.400 |
| 14/12/1999 | 13,16 | 13,44 | 12,94 | 13,31 | +0,47% | 3,80% | 328.400 |
| 13/12/1999 | 13,50 | 13,63 | 13,00 | 13,25 | -2,30% | 4,63% | 184.400 |
| 10/12/1999 | 13,00 | 13,63 | 13,00 | 13,56 | +3,83% | 4,81% | 289.600 |
| 09/12/1999 | 13,25 | 13,25 | 12,88 | 13,06 | -1,65% | 2,83% | 508.600 |
| 08/12/1999 | 13,06 | 13,31 | 12,88 | 13,28 | +1,43% | 3,35% | 796.400 |
| 07/12/1999 | 13,94 | 14,13 | 13,06 | 13,09 | -6,05% | 7,62% | 291.200 |
| 06/12/1999 | 13,84 | 14,09 | 13,00 | 13,94 | -1,76% | 7,90% | 417.600 |
| 03/12/1999 | 13,03 | 14,19 | 13,03 | 14,19 | +7,84% | 8,87% | 329.800 |
| 02/12/1999 | 13,22 | 13,25 | 12,97 | 13,16 | -1,64% | 2,13% | 202.200 |
| 01/12/1999 | 13,25 | 13,41 | 13,09 | 13,38 | +0,71% | 2,36% | 150.000 |
| 30/11/1999 | 13,03 | 13,41 | 12,94 | 13,28 | +1,92% | 3,60% | 677.400 |
| 29/11/1999 | 13,13 | 13,16 | 12,91 | 13,03 | -0,71% | 1,90% | 557.800 |
| 26/11/1999 | 12,88 | 13,19 | 12,88 | 13,13 | +0,48% | 2,43% | 155.600 |
| 24/11/1999 | 13,00 | 13,19 | 12,75 | 13,06 | -0,95% | 3,37% | 247.200 |
| 23/11/1999 | 12,56 | 13,19 | 12,56 | 13,19 | +3,94% | 4,98% | 584.800 |
| 22/11/1999 | 12,84 | 12,84 | 11,69 | 12,69 | -0,73% | 9,00% | 575.800 |
| 19/11/1999 | 13,25 | 13,25 | 12,50 | 12,78 | -1,68% | 5,66% | 203.600 |